Endowment Lock

UK-based pet pharmaceutical company Royal Hound, in collaboration with the Fédération Cynologique Internationale (FCI), is conducting an advanced clinical research project centered on canine health and well-being, garnering substantial international attention. This study aims to collect scientific data that can enhance overall canine health and facilitate disease prevention and management.

Through its collaboration with FCI, Royal Hound is conducting high-quality research that meets global standards, aiming to provide differentiated and tailored health solutions suited to various ages and breeds. A representative from Royal Hound stated, “We are committed to ongoing research and development to ensure that each dog receives the best healthcare tailored to its unique needs and characteristics. This partnership with FCI represents a significant advancement in enhancing pet health and well-being.”

The research will gather clinical data across various aspects of canine health, including cardiovascular health, immune system support, and joint health, to propose effective health management solutions for dogs. Furthermore, the findings are anticipated to contribute to advancements in pet healthcare and the establishment of enhanced health management protocols. Based on the collected data, RoyalHound aims to develop innovative approaches for early disease diagnosis and prevention, ultimately striving to improve the quality of life for pets.

As part of this project, Royal Hound plans to enhance communication with pet owners by offering a variety of programs that provide the latest information on health management. These initiatives will include online seminars, educational videos, and expert consultation services designed to raise awareness of canine health, empowering owners to take an active role in managing their pets’ well-being. Through these efforts, RoyalHound aims to transcend the traditional role of a product provider, positioning itself as a true partner in health management.